Study Analyzes Antiretroviral Drug Production, Cost Policies Of Brazil

Main Category: HIV / AIDS
Article Date: 14 Nov 2007 - 7:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

"Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment," PLoS Medicine: The study, conducted by Amy Nunn of the Harvard School of Public Health and colleagues, analyzes the costs of individual antiretroviral drugs in Brazil, finding that although generic drugs produced in Brazil often are more expensive than similar drugs produced in other countries, Brazil still offers lower prices for patented antiretrovirals than other developing countries. Brazil produces eight generic antiretrovirals, and since 2001 it has negotiated antiretroviral prices with five pharmaceutical companies, according to the study. The study concludes that although Brazil saved about $1 billion from 2001 to 2005 on antiretrovirals through its strategies, drug costs continued to increase as more people required treatment and HIV-positive people lived longer (PLoS Medicine release, 11/12).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.